ECSP19040190A - Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f - Google Patents

Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f

Info

Publication number
ECSP19040190A
ECSP19040190A ECSENADI201940190A ECDI201940190A ECSP19040190A EC SP19040190 A ECSP19040190 A EC SP19040190A EC SENADI201940190 A ECSENADI201940190 A EC SENADI201940190A EC DI201940190 A ECDI201940190 A EC DI201940190A EC SP19040190 A ECSP19040190 A EC SP19040190A
Authority
EC
Ecuador
Prior art keywords
compositions
pyridinoylpiperidine
methods related
ht1f agonists
ht1f
Prior art date
Application number
ECSENADI201940190A
Other languages
English (en)
Inventor
Emma Sharp
Brigida Allieri
Raymond D Skwierczynski
Paul Fagan
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19040190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of ECSP19040190A publication Critical patent/ECSP19040190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevos pseudopolimorfos de la sal de hemisuccinato de 2,4,6-trifluoro-N-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-benzamida que son útiles en composiciones farmacéuticas, por ejemplo, para el tratamiento y prevención de la cefalea migrañosa.
ECSENADI201940190A 2016-12-06 2019-06-06 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f ECSP19040190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
ECSP19040190A true ECSP19040190A (es) 2019-08-30

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201940190A ECSP19040190A (es) 2016-12-06 2019-06-06 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f

Country Status (38)

Country Link
US (1) US11053214B2 (es)
EP (1) EP3551617B1 (es)
JP (4) JP2020500936A (es)
KR (4) KR20250070124A (es)
CN (3) CN115385894A (es)
AU (1) AU2017373784B2 (es)
BR (1) BR112019010934A2 (es)
CA (1) CA3043772C (es)
CL (1) CL2019001426A1 (es)
CO (1) CO2019005290A2 (es)
CR (1) CR20190251A (es)
CY (1) CY1124540T1 (es)
DK (1) DK3551617T3 (es)
DO (1) DOP2019000139A (es)
EA (1) EA201991112A1 (es)
EC (1) ECSP19040190A (es)
ES (1) ES2889476T3 (es)
HR (1) HRP20211557T1 (es)
HU (1) HUE056820T2 (es)
IL (1) IL266598B2 (es)
JO (1) JOP20190129B1 (es)
LT (1) LT3551617T (es)
MA (1) MA52920B1 (es)
MD (1) MD3551617T2 (es)
MX (2) MX392547B (es)
MY (1) MY196855A (es)
NZ (1) NZ752906A (es)
PE (2) PE20241297A1 (es)
PH (1) PH12019501252B1 (es)
PL (1) PL3551617T3 (es)
PT (1) PT3551617T (es)
RS (1) RS62415B1 (es)
SI (1) SI3551617T1 (es)
TN (1) TN2019000174A1 (es)
TW (1) TWI671290B (es)
UA (1) UA124433C2 (es)
WO (1) WO2018106657A1 (es)
ZA (1) ZA201903449B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010359A (es) 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
EP4333815A1 (en) 2021-05-07 2024-03-13 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
MX2011010359A (es) * 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CN114213393A (zh) 2016-07-15 2022-03-22 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
KR20190075130A (ko) 2019-06-28
PH12019501252B1 (en) 2024-05-24
JP2020500936A (ja) 2020-01-16
CN115385894A (zh) 2022-11-25
EP3551617B1 (en) 2021-08-11
JOP20190129A1 (ar) 2019-05-29
IL266598A (en) 2019-07-31
JP2023123678A (ja) 2023-09-05
CL2019001426A1 (es) 2019-10-11
JP2024178323A (ja) 2024-12-24
TWI671290B (zh) 2019-09-11
SI3551617T1 (sl) 2021-11-30
MX392547B (es) 2025-03-24
TN2019000174A1 (en) 2020-10-05
NZ752906A (en) 2021-07-30
JP2022000451A (ja) 2022-01-04
CO2019005290A2 (es) 2019-05-31
CA3043772C (en) 2022-06-07
MY196855A (en) 2023-05-05
UA124433C2 (uk) 2021-09-15
KR20230008257A (ko) 2023-01-13
IL266598B1 (en) 2024-01-01
CA3043772A1 (en) 2018-06-14
PT3551617T (pt) 2021-10-04
CR20190251A (es) 2019-08-26
CN110291079A (zh) 2019-09-27
HRP20211557T1 (hr) 2022-01-07
ES2889476T3 (es) 2022-01-12
ZA201903449B (en) 2021-02-24
TW201833097A (zh) 2018-09-16
JP7561240B2 (ja) 2024-10-03
KR20210102497A (ko) 2021-08-19
BR112019010934A2 (pt) 2019-10-01
US20200087279A1 (en) 2020-03-19
PE20241297A1 (es) 2024-06-24
CY1124540T1 (el) 2022-07-22
MX388091B (es) 2025-03-19
RS62415B1 (sr) 2021-10-29
MD3551617T2 (ro) 2021-12-31
JP7818666B2 (ja) 2026-02-20
DK3551617T3 (da) 2021-09-13
MX2021014139A (es) 2022-05-24
KR20250070124A (ko) 2025-05-20
EP3551617A1 (en) 2019-10-16
PH12019501252A1 (en) 2019-12-02
MX2019006520A (es) 2019-08-21
MA52920A (fr) 2021-04-28
PL3551617T3 (pl) 2021-12-20
HUE056820T2 (hu) 2022-03-28
AU2017373784A1 (en) 2019-05-16
IL266598B2 (en) 2024-05-01
WO2018106657A1 (en) 2018-06-14
DOP2019000139A (es) 2019-08-15
US11053214B2 (en) 2021-07-06
AU2017373784B2 (en) 2020-04-23
JOP20190129B1 (ar) 2023-03-28
LT3551617T (lt) 2021-10-11
CN115385893A (zh) 2022-11-25
MA52920B1 (fr) 2021-11-30
EA201991112A1 (ru) 2019-10-31
PE20191134A1 (es) 2019-09-02

Similar Documents

Publication Publication Date Title
ECSP19040190A (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
ZA202502750B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
CL2019001344A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2019014228A (es) Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia.
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CO2019014647A2 (es) Composiciones inmunogénicas
MX2019005089A (es) Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX394254B (es) Composiciones para el tratamiento de dermatitis atópica canina y sus usos.
MX2017007318A (es) Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2018004091A (es) Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci